-
This Analyst Just Tripled Intrexon's Zika Drug Sales Estimates
Thursday, July 7, 2016 - 8:33am | 290Read More...Intrexon Corp (NYSE: XON) faces a large, multi-segment market opportunity, which outweighs near-term pressures related to its 2Q16 results, Wunderlich’s Ryan MacDonald said in a report. He reiterated a Buy rating on the company, with a price target of $50. Intrexon’s Oxitec business...
-
This Stock Is Winning From Brazil's Approval Of Genetically Engineered Mosquitoes
Wednesday, April 13, 2016 - 4:35pm | 310Read More...Shares of Intrexon Corp (NYSE: XON) surged as much as 9 percent after its Oxitec unit won a temporary approval from Brazil's Health Agency Anvisa to deploy its genetically engineered mosquito, OX513A, throughout the country. In a press release, Oxitec said its OX513A biologically controls...
-
World Health Organization Declares Zika Virus An International Public Health Emergency
Monday, February 1, 2016 - 4:32pm | 224Read More...Various media sources, such as the New York Times, are reporting that the World Health Organization has declared the Zika virus and its supposed links to birth defects an international public health emergency. The Zika virus is transmitted by mosquitoes and has been linked to cases in more than 20...
-
Intrexon Spikes 20%; Oxitec Subsidiary Working To Control Zika Virus Outbreak
Thursday, January 28, 2016 - 1:34pm | 196Read More...Shares of Intrexon Corp (NYSE: XON) were trading higher by more than 12 percent at $29.69 early Thursday afternoon. Intrexon is engaged in the field of synthetic biology. The company designs, builds and regulates gene programs which are Deoxyribonucleic Acid (DNA) sequences that consist of...
